financetom
Business
financetom
/
Business
/
SentinelOne Fiscal Swings to Profit in Q2, Revenue Rises; Issues Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SentinelOne Fiscal Swings to Profit in Q2, Revenue Rises; Issues Outlook
Aug 29, 2024 8:19 AM

04:31 PM EDT, 08/27/2024 (MT Newswires) -- SentinelOne ( S ) reported a fiscal Q2 Non-GAAP net income late Tuesday of $0.01 per diluted share, compared with a loss of $0.08 a year earlier.

Analysts polled by Capital IQ expected a break-even per share.

Revenue for the quarter ended July 31 was $198.9 million, up from $149.4 million a year earlier.

Analysts surveyed by Capital IQ expected $197.4 million.

The company expects fiscal Q3 revenue of $209.5 million. Analysts expect $209.7 million.

For fiscal 2025, it expects revenue of $815 million. Analysts are looking for $813.7 million.

Price: 24.40, Change: -0.35, Percent Change: -1.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Oct 17, 2024
* Ingram, PE firm seek to raise as much as $428 mln * Platinum Equity will remain controlling shareholder post-IPO * Ingram set to go public again, 28 years after initial NYSE debut (Adds background on company and IPO details in paragraphs 4-12) Oct 15 (Reuters) - Ingram Micro is targeting a valuation of up to $5.42 billion in its...
S&P Global Names Eric Aboaf CFO
S&P Global Names Eric Aboaf CFO
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- S&P Global ( SPGI ) said Tuesday that it has named Eric Aboaf as its chief financial officer, effective February. Aboaf was most recently the CFO of State Street (STT). Price: 528.96, Change: +1.44, Percent Change: +0.27 ...
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Oct 17, 2024
08:59 AM EDT, 10/15/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday its phase 2/3 Vibrance-MG study of nipocalimab in adolescents with generalized myasthenia gravis met its primary endpoint by achieving sustained disease control. Treatment with nipocalimab plus standard of care reduced immunoglobulin G levels by 69% over 24 weeks, the company said. The combination treatment also...
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said its Mexican affiliate has obtained regulatory approval for Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that aren't eligible for autologous stem cell transplantation. The treatment is expected to launch in the first half of next...
Copyright 2023-2025 - www.financetom.com All Rights Reserved